Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recaticimab for reversal of coronary atherosclerotic plaques (REVERS trial)
ChiCTR2600120692Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recaticimab in coronary arteriosclerosis and hyperlipidemia (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: NCPV score at week 48. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
recaticimab
03
Conditions
coronary arteriosclerosishyperlipidemia
Beyond the preview
Go deeper on ChiCTR2600120692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120692.